• TECFIDERA demonstrates strong clinical and MRI efficacy in newly diagnosed and overall patient populations vs. placebo1,2
  • TECFIDERA has a favourable safety and tolerability profile which is maintained over long-term treatment3-6
  • TECFIDERA is a convenient twice daily oral presentation1


TECFIDERA is indicated in adults for the treatment of relapsing remitting multiple sclerosis (RRMS).1

Biogen-32896. Date of preparation: January 2020